What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › Type 2 diabetes › albiglutide

albiglutide in type 2 diabetes

albiglutide is not approved in the US for type 2 diabetes, and has 17 trials on file here in this condition. 13 of them are phase 3 or later. No trial here has a completion date still in the future, so this is a closed body of work rather than an active programme. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

17 registered trials study albiglutide (Tanzeum) in type 2 diabetes. None has a scheduled reporting date on file.

Trials on file
17
Active
0
Active phase 3
0
Participants in active trials
0
Sponsors
1
Scheduled readouts
0

All trials on file

Every registered trial of albiglutide grouped under type 2 diabetes, largest first. Grouping follows the registry’s own condition wording.

TrialStatusPhaseSponsor
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT00838903
CompletedP3GlaxoSmithKline
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
NCT02229227
CompletedP3GlaxoSmithKline
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00838916
CompletedP3GlaxoSmithKline
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00839527
CompletedP3GlaxoSmithKline
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
NCT00976391
CompletedP3GlaxoSmithKline
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
NCT01098539
CompletedP3GlaxoSmithKline
Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056
CompletedP3GlaxoSmithKline
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017
CompletedP3GlaxoSmithKline
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
NCT02683746
CompletedP3GlaxoSmithKline
Pharmacokinetics/Pharmacodynamics of Albiglutide
NCT01357889
CompletedP2GlaxoSmithKline
Dose Ranging Study of Albiglutide in Japanese Subjects
NCT01098461
CompletedP2GlaxoSmithKline
In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
NCT00354536
CompletedP2GlaxoSmithKline
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
NCT01475734
CompletedP2GlaxoSmithKline
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
NCT02496221
CompletedP4GlaxoSmithKline
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
NCT02750930
TerminatedP4GlaxoSmithKline
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02229240
WithdrawnP3GlaxoSmithKline
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
NCT03015519
WithdrawnP3GlaxoSmithKline

See the full record for albiglutide, or every molecule being studied in type 2 diabetes. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.